Trial results

A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

NCT06643728 on ClinicalTrials.gov · last registry update 2026-05-26

An unusually large phase 2: 252 participants, more than double the 114 typical for the stage. The sponsor logged completion for 16 January 2026. Primary outcome, as filed: Percent Change from Baseline in Body Weight. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status

ACTIVE_NOT_RECRUITING

Phase

P2

Drug

tirzepatide

Zepbound, Mounjaro

Sponsor

Eli Lilly and Company

Sponsor type

Industry

Enrollment

252

Started

2024-10-21

Primary completion

2026-01-16 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percent Change from Baseline in Body Weight

Conditions studied

Obesity · Overweight

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.